Favrille’s Acquisition Of Diversa CD20 Antibodies Bolsters Lead Lymphoma Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Another firm developing a therapeutic vaccine for lymphoma, Biovest, says it hopes to launch its BiovaxID product in mid-2009.
You may also be interested in...
Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure
Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.
Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure
Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.
Biovest Ends Therapeutic Cancer Vaccine Trial Early On Positive DMC Signal
Firm seeks “accelerated or conditional” approval path from FDA.